Related Experiment Video
Updated: Aug 30, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Psychotropic drug-induced weight gain alleviated with orlistat: a case series
Thomas L Schwartz1, Mark Beale
1Upstate Medical University, State University of New York, Syracuse, New York, USA. schwartzresearch1@yahoo.com
Abstract:
Weight gain is a common side effect associated with antidepressant, anxiolytic, and antipsychotic drug use. Obesity is a risk factor for several other disorders, including hypertension, diabetes, and coronary artery disease. To date, there have been few safe, well-tolerated, and effective pharmacological agents available to alleviate weight gain in general, and virtually no studies specific to psychiatric drug-induced weight gain. This case series looks at the use of orlistat, a reversible inhibitor of lipases approved by the US Food and Drug Administration for obesity management, naturalistically in 13 patients with weight gain secondary to psychotropic drug use. The results showed that orlistat, administered in 3 daily doses with meals, was safe, well-tolerated, and effective, resulting in an average weight loss of 35% during an acute treatment period of about 3 months.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Dosing: Obese Patients
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: Overview
